

ML18

The Best of Both Worlds: AI and Human-in-the-Loop Processing in TLF Design, Production, and Validation

- Ilan Carmeli, Beaconcure COO and Co-Founder
- Steve Ross, Director of Statistics and Life Sciences
- Consultancy

March 18, 2025

Warm Up Questions

- How many of you are working in CRO/Pharma?
- How many of you are stats programmers or data scientists?
- How many of you have a detailed document or place with all the metadata needed for the phase from ADaM to TLFs?



Our Goal


Reduce double programming by 85%
in the phase of ADaM to TLFs using a
metadata approach

Why?


In more than 30% of cases, even for standard tables, it is very difficult to replicate the same process.

How?

Following the same **procedures** of the software development space with some adaptations.



TLF Development and Review: One Deliverable



What Should the Human-Machine Partnership Look Like?



Humans

- **Endpoint definition**, characterization
- Study conceptualization and design
- **Review, coalesce, interpret**
- Drive **continuous process improvement** for AI algorithms



Verify AI

- **Parse and understand** multiple document types
- **Automate review** with NLP, NER, RAG
- **Generate TLFs automatically** with HITL
- **Continually self-improve** AI models and algorithms



How can we leverage/reuse the metadata acquired in one trial many times over?

Verify's Dynamic Core

AI-Enabled Parsing and Results Metadata Extraction



Drag & Drop

Create Project

1 File 2 Info 3 Analysis 4 Share

+ Add files

Category Files Size

- Project name 0 files 0 kb
- LoT XLSX 0 files 0 kb
- Mock Shell DOCX 0 files 0 kb
- ADaM ADAE SAS7BDT 3 MORE 0 files 0 kb
- Tables & listings HTML RTF 0 files 0 kb
- Figures RTF 0 files 0 kb

Drag & Drop
Study output folder here

Verify will sort the files for you!

Previous Next

Parse & Ingest

Table 14.1.1.13

Treatment Emergent Adverse Event Leading to Discontinuation of Study Drug
Organ Class and Preferred Term Treatment Related Safety Pop


	Treatment				Treatment				M
	Mild	Mod.	Sev.	Total	Mild	Mod.	Sev.	Total	
Any TEAEs	1 (0.8%)	0 (3.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)	1
Infection	1 (0.8%)	0 (3.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (1.0%)	2 (2.0%)	2 (2.0%)	1
Bronchitis viral	1 (0.8%)	0 (3.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (1.0%)	2 (2.0%)	2 (2.0%)	1

N = number of subjects in the specified group, or the total sample; this value is the denominator for the percentage calculation. Subjects are only counted once per event in each row.
BEACONCURE CONFIDENTIAL SDTM Creation: 08OCT2021 (00:55) Source Data: adae Table Generation: 01OCT2021

AESEV	AEREL	TRTA	SAFFL	AESUBJDC	AECN	AEDECOD
MILD	RELATED	DRUG B	Y	Y	DOSE NOT CHANGED	SARS-CoV-2 test positive
MODERATE	RELATED	DRUG B	Y	N	DOSE NOT CHANGED	Nasopharyngitis
MILD	RELATED	DRUG A	Y	N	DRUG WITHDRAWN	Diarrhea
MILD	RELATED	DRUG A	N	N	DOSE NOT CHANGED	Chalazion
MODERATE	NOT RELATED	DRUG B	N	N	DRUG INTERRUPTED	Hordeolum left eye
MODERATE	NOT RELATED	DRUG B	N	N	UNKNOWN	Diarrhea
SEVERE	RELATED	DRUG B	N	N	DOSE NOT CHANGED	Supraventricular extrasystole
MILD	RELATED	DRUG A	Y	Y	DOSE NOT CHANGED	Bronchitis viral
MODERATE	RELATED	DRUG B	Y	Y	DRUG WITHDRAWN	Diarrhea
SEVERE	RELATED	DRUG B	Y	N	DRUG INTERRUPTED	Dry eye
SEVERE	NOT RELATED	DRUG A	N	N	DOSE NOT CHANGED	Tachycardia
SEVERE	RELATED	DRUG A	N	N	DOSE NOT CHANGED	Diarrhea
SEVERE	RELATED	DRUG B	Y	N	DRUG WITHDRAWN	Diarrhea
MILD	NOT RELATED	DRUG A	Y	N	DOSE NOT CHANGED	Hordeolum left eye
SEVERE	RELATED	DRUG B	Y	N	DOSE NOT CHANGED	SARS-CoV-2 test positive
MODERATE	NOT RELATED	DRUG A	N	N	UNKNOWN	Diarrhea

AI-Enabled Output Generation with HITL Feedback

1. Verify **parses TLFs, extracts and links** data and results metadata
2. Verify **checks** your outputs (format, arithmetic, within-table, cross-table)
3. Verify identifies **linkages** between **ADaM** and **tables***
4. Verify incorporates **SME feedback** via the Metadata Curator
5. Verify **continually improves accuracy**



Best of Both Worlds Use Case

AI-Enabled Output Generation with HITL Feedback

Programmer-Generated Table

N=5

Table 14.3.2.5.2
BE-0552543 Protocol A1234567
Treatment-Emergent Adverse Events by System Organ Class (Treatment Related, Immunogenicity Sub-study Analysis Set)

	Placebo (N=9)	BE-0552543 100mg QD (N=5)	BE-0552543 200mg QD (N=11)
Number of Subjects Evaluable for AEs			
Number (%) of Subjects: by SYSTEM ORGAN CLASS	n (%)	n (%)	n (%)

Verify-Generated Table

N=6

Generate by Verify
Table 14.3.2.5.2
BE-0552543 Protocol A1234567
Treatment-Emergent Adverse Events by System Organ Class (Treatment Related, Immunogenicity Sub-study Analysis Set)

	Placebo (N=9)	BE-0552543 100mg QD (N=6)	BE-0552543 200mg QD (N=11)
Number of Subjects Evaluable for AEs			
Number (%) of Subjects: by SYSTEM ORGAN CLASS	n (%)	n (%)	n (%)

Compare & Decide:
Update TLF title or subset

ADAM Dataset

N=6

Unique Subject Identifier	Full Analysis Set Population Flag	Safety Population Flag	Per-Protocol Population Flag	Completers Population Flag	Randomized Population Flag	Immunogenicity Substudy Analysis Flag	Description of Planned Arm	Planned Arm Code	Description of Actual Arm	Actual Arm Code
USUB.	FASFL	SAFFL	PPROTFL	COMPLFL	RANDFL	ISSFL	ARM	ARMCD	ACTARM	ACTARMCD
A1234567 1001 10015001	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D
A1234567 1001 10015002	N	N	N	N	N	N	SCREEN FAILURE	SCRNFAIL	SCREEN FAILURE	SCRNFAIL
A1234567 1001 10015003	Y	Y	Y	Y	Y	N	Placebo	A	Placebo	A
A1234567 1001 10015004	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D
A1234567 1001 10015005	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D
A1234567 1001 10015006	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	A	BE-0552543 100mg QD	A
A1234567 1001 10015007	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D
A1234567 1001 10015008	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D
A1234567 1001 10015009	Y	Y	Y	Y	Y	Y	BE-0552543 100mg QD	D	BE-0552543 100mg QD	D

← 14.1.1.13

− 100 +



Table 14.1.1.13
 Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug by System Organ Class and Preferred Term Treatment Related Safety Population

	Drug A (N=119)				Drug B (N=109)			
	Mild	Mod.	Sev.	Total	Mild	Mod.	Sev.	Total
Any TEAEs	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Infection	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Bronchitis viral	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)

N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculation. Subjects are only counted once per event in each row.
 BEACONCURE CONFIDENTIAL SDTM Creation: 08OCT2021 (00:55) Source Data: adae Table Generation: 09OCT2021

Metadata Alignment



Review the current alignment between table entity and ADaM column and values. Revise if necessary.

Table Entity ADaM Column ADaM Value(s)

Title

Treatment-Emergent TRTEMFL Y

Leading to Discont... AEACN DRUG WI...

Treatment Related AEREL RELATED

Safety Population SAFFL Y

Column/Row Headers

Major (Treatment) TRTA

Minor (Severity) AESEV

Cancel

Save

Automate Reuse of Context-Rich Results Metadata

- **Human-in-the-loop (HITL) feedback**
 - Modify metadata alignment between table entities and ADaM
 - Alignment saved and applied to subsequent checks and analyses
- **Compatibility with CDISC ARS framework**
- **Basis for automated output generation**
- **Activity Log** automatically records changes

Table 14.1.1.13
Leading to Discontinuation of Study Drug

Title Entity Alignment

Leading to discontinuation of study drug

Entity: AESUBJLOC

Value: Y

Drug A (N=119)				
	Mild	Mod.	Sev.	Total
Any TEAEs	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Infection	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Bronchitis viral	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)

N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations. Subjects are only counted once per event in each row.
BEACONCURE CONFIDENTIAL SDTM Creation: 09OCT2021 (08:55) Source Data: adae Table Generation: 09OCT2021

Generated by Verify

Table 14.1.1.13
Treatment Emergent Adverse Events Leading to Discontinuation of Study Drug by System Organ Class and Preferred Term (Treatment Related) - Safety Population


	Drug A (N=119)				Drug B (N=109)				Total (N=219)			
	Mild	Mod.	Sev.	Total	Mild	Mod.	Sev.	Total	Mild	Mod.	Sev.	Total
Any TEAEs	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)	1 (0.5%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Infection	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)	1 (0.5%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Bronchitis viral	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)	1 (0.5%)	0 (0.0%)	2 (2.0%)	2 (2.0%)

N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations. Subjects are only counted once per event in each row.
BEACONCURE CONFIDENTIAL SDTM Creation: 09OCT2021 (08:55) Source Data: adae Table Generation: 09OCT2021

Metadata Curator Process Map: Current User and Verify Flow

■ User flow (Statistical Programmer)

■ Verify flow - AI-enabled table generation and checks



Evolution of Clinical Research Analytics: Human-AI Integration



AI Processing Pipeline

- Document parsing
- Entity extraction
- Relationship mapping
- Automated validation checks
- Discrepancy identification



Human Review Interface

- Clear presentation of AI-identified elements
- Intuitive tools for reviewing and modifying metadata
- Feedback capture mechanisms
- Activity logging for audit trails



Learning Loop

- Capture of human decisions and corrections
- Integration of feedback into training data
- Continuous model improvement
- Performance monitoring and metrics

Verify Benefits and Outcomes



Speed

- Shorter Review Cycles
- Reduced Review Effort
- Enhanced Accuracy



Efficiency

- Reduced Spreadsheet Maintenance
- Fewer Email Chains
- Scalable Growth



Visibility

- Centralized Management
- Enhanced Executive Oversight
- Transparent Audit Trail

Thank You!

llan@beaconcure.com

Steve@beaconcure.com